Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 30;29(1):23.
doi: 10.1186/s12929-022-00806-1.

Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far

Affiliations
Review

Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far

Marzanna Łusiak-Szelachowska et al. J Biomed Sci. .

Abstract

Bacteriophages (phages) may be used as an alternative to antibiotic therapy for combating infections caused by multidrug-resistant bacteria. In the last decades, there have been studies concerning the use of phages and antibiotics separately or in combination both in animal models as well as in humans. The phenomenon of phage-antibiotic synergy, in which antibiotics may induce the production of phages by bacterial hosts has been observed. The potential mechanisms of phage and antibiotic synergy was presented in this paper. Studies of a biofilm model showed that a combination of phages with antibiotics may increase removal of bacteria and sequential treatment, consisting of phage administration followed by an antibiotic, was most effective in eliminating biofilms. In vivo studies predominantly show the phenomenon of phage and antibiotic synergy. A few studies also describe antagonism or indifference between phages and antibiotics. Recent papers regarding the application of phages and antibiotics in patients with severe bacterial infections show the effectiveness of simultaneous treatment with both antimicrobials on the clinical outcome.

Keywords: Animal model; Antibiotic; Bacteriophage; Human phage therapy; Phage–antibiotic synergy.

PubMed Disclaimer

Conflict of interest statement

AG, BWD and RM are co-inventors for patents covering preparation and application of therapeutic phages owned by the Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland. Other authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
The most important PAS mechanisms leading to positive synergy

References

    1. Kutter EM, Kuhl SJ, Abedon ST. Re-establishing a place for phage therapy in western medicine. Future Microbiol. 2015;10:685–688. doi: 10.2217/fmb.15.28. - DOI - PubMed
    1. Chanishvili N. Bacteriophages as therapeutic and prophylactic means: summary of the Soviet and post Soviet experiences. Curr Drug Deliv. 2016;13:309–323. doi: 10.2174/156720181303160520193946. - DOI - PubMed
    1. Górski A, Międzybrodzki R, Weber-Dąbrowska B, Fortuna W, Letkiewicz S, Rogóż P, et al. Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front Microbiol. 2016;7:1515. doi: 10.3389/fmicb.2016.01515. - DOI - PMC - PubMed
    1. Anand T, Virmani N, Kumar S, Mohanty AK, Pavulraj S, Bera BC, et al. Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model. J Glob Antimicrob Resist. 2020;21:34–41. doi: 10.1016/j.jgar.2019.09.018. - DOI - PubMed
    1. Geng H, Zou W, Zhang M, Xu L, Liu F, Li X, et al. Evaluation of phage therapy in the treatment of Staphylococcus aureus-induced mastitis in mice. Folia Microbiol (Praha) 2020;65(2):339–351. doi: 10.1007/s12223-019-00729-9. - DOI - PubMed

Substances

LinkOut - more resources